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Abstract
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Before biomarkers can be used in clinical trials or patients’ management, the laboratory assays
that measure their levels have to go through development and analytical validation. One of the
most critical performance metrics for validation of any assay is related to the minimum amount
of values that can be detected and any value below this limit is referred to as below the limit
of detection (LOD). Most of the existing approaches that model such biomarkers, restricted
by LOD, are parametric in nature. These parametric models, however, heavily depend on the
distributional assumptions, and can result in loss of precision under the model or the distributional
misspecifications. Using an example from a prostate cancer clinical trial, we show how a critical
relationship between serum androgen biomarker and a prognostic factor of overall survival is
completely missed by the widely used parametric Tobit model. Motivated by this example, we
implement a semiparametric approach, through a pseudo-value technique, that effectively captures
the important relationship between the LOD restricted serum androgen and the prognostic factor.
Our simulations show that the pseudo-value based semiparametric model outperforms a commonly
used parametric model for modeling below LOD biomarkers by having lower mean square errors
of estimation.
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1.

Introduction
Biomarkers are known to play an important role in the disease progression in several
diseases, such as oncology and cardiology and as such they have been extensively used
in drug development1,2. Before biomarkers can be used in patient management or a
clinical trial, laboratory assays measuring their levels need to undergo analytical validation.
Occasionally values of the markers are so low that they are not detected by the measuring
instruments or assays3. These observations are known as below the limit of detection (LOD)

**

Corresponding Author: susan.halabi@duke.edu.
Data Availability Statement
The clinical trials data used in this article can be obtained through the NCI Data Archive.

Dutta and Halabi

Page 2

Author Manuscript

or non-detects4,5. A large proportion of non-detects for a biomarker in a study would cause
serious effects, irrespective if the biomarker is the main outcome or a covariate. Single
or multiple detection limits can occur depending on whether the biomarker data contain
measurements from one or multiple laboratories. Multiple detection limits can also occur
in disease studies when scientists analyze a combination of multiple biomarkers and these
biomarkers differ in their detection limits. Deleting observations below the LOD can lead
to underpowered inference or biased results and thus it is critical to implement appropriate
methods to optimally utilize the values below the LOD.

Author Manuscript
Author Manuscript

A common approach is to replace the values below the LOD by a either the LOD or
LOD/2.6,7 This strategy, however, introduces artificial skewness to the data that may
lead to a biased inference. Alternative approaches have been suggested4,8,9 to obtain
summary measures of variable having observations below the LOD. However, most of
these approaches involve imputations under strong distributional assumptions which has
been known to perform poorly in case of mis-specified models with large proportions
of non-detects10. Moreover, calculating only the summary measures of biomarkers below
the LOD is not sufficient to ascertain its importance in clinical studies. It is critical to
establish a direct relationship of such a biomarker with some explanatory variables in
a disease process. Model- based approaches are widely used in establishing such direct
associations. The Tobit model11,12 is the one of the earliest and most popular model-based
approach for observations below LOD as evident from its wide use in various fields of
medicine and epidemiology13,14,15,16. It uses a likelihood-based approach for estimating
model parameters under a normality assumption. There have been recent advancements
to such model-based approaches by varying the underlying distributional assumptions,
e.g., mixtures of normal and skew-normal distributions17,18,19 and skewed t-distributions20.
These parametric approaches are heavily dependent on the knowledge of the underlying
distribution, and thus the estimates obtained from them may lead to highly unstable and
biased results if the underlying true distribution of the biomarker data deviates from the
distributional assumption of the model. This is especially the case when there is a large
proportion of non-detects. One such scenario is discussed through a motivating example of
a prostate cancer clinical trial, where a widely used parametric model fails to identify an
important relationship between a serum androgen and a prognostic factor of prostate cancer
survival.

Author Manuscript

The motivation behind this article is to develop a modeling approach, for biomarkers
restricted to LODs, which is robust to the choice of the underlying distribution of the
biomarker while producing accurate inference on the biomarker. Moreover, most of the
existing parametric models, based on likelihood approaches, were developed mainly to
address single lower LOD scenarios without any known optimal way to tackle situations
where multiple LODs can occur in the same data. However, such multiple LODs can
co-exist if the same biomarker is measured in different laboratories in different batches or
if multiple biomarkers, with varying detection limits, are combined to obtain a classifier.
In this article, we propose a semiparametric approach of modeling biomarkers subjected to
LOD through a pseudo-value approach which is distribution-free and can uniformly handle
single as well multiple LODs is the same data. The pseudo-values have been previously
implemented in regression of complex quantities in time-to-event analysis21,22,23,24,25;
Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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however, we extend this approach in modeling biomarkers below LOD for the first time.
We implement a semiparametric inference procedure for the biomarkers below the LOD
by enabling a pseudo-value based estimation through a generalized estimating equation
framework. Then, the resulting inference becomes robust, free from any rigid distributional
assumptions, while being efficient as well. This is demonstrated through the several
simulations where our proposed method has lower errors of estimation compared to a
popular parametric model. Moreover, in our motivating example from a prostate cancer
clinical trial, our proposed semiparametric method outperformed the widely used parametric
method by identifying a significant association between the LOD restricted serum androgen
biomarker and an important prognostic factor of overall survival. Although our method
is based on the concept of pseudo-values, its implementation in modeling biomarker data
below the LOD is a novel application which leads to a useful semi-parametric alternative to
the standard parametric approaches.

Author Manuscript

The rest of the article is organized as follows. We describe the pseudo-value based
semiparametric modeling of observations below the LOD in Section 2. In Section 3,
we conduct several simulations to investigate the performance of the proposed approach
compared to a standard parametric approach. In Section 4, we revisit our motivating
example of a prostate cancer data analysis, along with another real-life example of serum
cotinine analysis from the NHANES data, and we discuss the overall results and their
implications in Section 5.

2.

Method

2.1

Construction of pseudo-values

Author Manuscript

Our method is based on a two steps approach. In the first step of our semiparametric model
is to create the pseudo-values. Suppose Xi is the observed biomarker value (in original
or a log-transformed scale) of ith unit in the sample and Zi is the vector of explanatory
variables or covariates corresponding to the ith unit in a set of n i.i.d observations. Let
E(Xi) = θ be the marginal mean and θi = E(Xi|Zi) be the conditional expectation given the

covariates. Suppose θ^ is an estimator of marginal mean θ and θ^−i is the “leave-one-out”

estimator of θ obtained from the remaining data after deleting the ith observation. Note that,
all the Xis may not be complete, since there are biomarker measurements below the LOD
which are not accurately recorded. For example, if the true biomarker value (Xj*) of the
jth unit is below LOD, then the recorded biomarker value for the jth unit is Xj = LOD >
Xj*. This means that observations below a LOD are essentially left-censored. This feature

of the data has to be taken into account while computing the marginal estimator θ^ and

Author Manuscript

the subsequent “leave-one-out” estimators θ^−i, i = 1,2,…, n. Therefore, to account for the

left-censored biomarker values below the LOD, we employ a nonparametric Kaplan-Meier26
based estimator of mean response for obtaining θ^ and θ^−i, i = 1, 2, …, n. Then, for a data with

n observations, the biomarker pseudo-value corresponding to the ith observation is defined
as
θ i = nθ − (n − 1)θ −i,

i = 1, 2, …, n

Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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Note that, the pseudo-values are obtained for all the n observations irrespective of whether
the biomarker value is below the LOD, i.e. left-censored, or not. Here, the pseudo-value
for the unit i measures the contribution of the unit i on the overall mean estimate of the
biomarker variable. Therefore, the pseudo-value θ^i can be regarded as an estimate of θi =

E(Xi|Zi), the conditional mean given the covariates.
2.2

Semiparametric modeling using the pseudo-values
In the second step, we use the pseudo-values instead of the observed biomarker values, as
the response variables for modeling the biomarkers given the covariates. We formulate the
relationship between θi and Zi through a generalized linear model of the form
g(θi) = βT Zi, i = 1, 2, …, n .

Author Manuscript

Here, β is the coefficient vector and g(.) is a suitable link function. For modeling the
biomarkers, we choose identity link as a choice for g(.), although other choices, e.g. log-link
for count data, are also possible. With the pseudo-values θ^i (i = 1,2, …, n) being treated as
the observed values of the mean response θi and Zis as explanatory variables, we estimate
the coefficient β through a generalized estimating equation (GEE) given below.
U(β) =

n

∑

i=1

U i(β) =

n

∑

i=1

∂ −1 T
g (β Zi)V i−1 θ i − g−1(βT Zi) = 0 .
∂β

Here, Vi is a working variance for θ^i. The variance estimates of β^ is obtained through the

Author Manuscript

standard sandwich estimator as follows:
−1

−1
var(U(β))I(β )
n
∂ −1 T
∂ −1 T
g (β Zi) V i−1
g (β Zi) , var(U(β)) =
where I(β) = ∑i = 1
∂β
∂β

S = I(β )

~

(-

) (-

)-

n

T

∑i = 1 Ui(β )Ui(β )

.

The use of the generalized estimating equation27 and the sandwich variance estimator,
makes the pseudo-value model robust to model and distributional misspecifications.

Author Manuscript

The large-sample properties of pseudo-value based regression methods in various settings
have been examined in Overgaard et al.28, Overgaard et al.29, Graw et al.30 among others.
In particular, Overgaard et al.28 showed that, under a general framework with independent
censoring and certain regularity conditions, the estimated regression coefficients from the
pseudo-value method are consistent and asymptotically normally distributed. The reader is
referred to in Overgaard et al.28 for more details on the regularity conditions.

3.

Simulation Studies

3.1

Simulation Settings
Simulation setting 1: Single lower limit of detection—Let Xi be the ith observation
for the variable of interest and Zi be the vector of explanatory variables or covariates
Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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corresponding to the ith observation in a set of n i.i.d observations. We use models for
E(log(X)) via the identity link. The outcomes are generated using the following model:
log(Xi) = β0 + β1ZGi + β2ZBi + ϵi , i = 1, 2, …, n

where β0 = 0, ZG is a continuous covariate with samples drawn from N(0, 0.5), and ZB is
a binary covariate with samples drawn from Bernoulli distribution with success probability
of 0.4. Here, Zi = (ZGi,ZBi). The errors are generated from one of the two following two
distributions:

Author Manuscript

i.

Extreme-valued distribution such that exp(ϵ) follows a Weibull distribution with
shape parameter 0.3 and scale parameter 3, to generate a skewed distribution

ii.

Normal distribution with mean 0 and variance 4 to generate a symmetric
distribution.

We choose two different sample sizes (n), 60 and 300, to evaluate the performances of the
proposed method under small and large sample size scenarios. We consider two choices
for the lower limit of detection: the tenth percentile or the twenty-fifth percentile. This
means that the lowest 10% or the lowest 25% of the sample biomarker values are set as
observations below the LOD.

Author Manuscript

We apply the semiparametric pseudo-value (PV) model for estimating the regression
coefficients. In addition, we use the parametric Tobit regression approach for left-censored
outcome to investigate the comparative performance of the PV model. We used the Tobit
regression approach because it is one of the most popular parametric models for analyzing
LOD restricted responses and has been found out to be the most powerful by Wiegend
et al.14 in certain scenarios among a set of popular parametric models which included
imputation based models, Bernoulli-Gaussian mixture models17,31, and nonparametric
Buckley-James estimator based regression models32. The Tobit model is based on the
assumption that the response variables are normality distributed. For a Tobit Model, if the
true biomarker value of the jth unit is Xj* and the recorded biomarker value for the jth
unit is Xj, then Xj =

Xj*

LOD

if Xj* > LOD
otℎerwise

and Xj is modeled using log(Xj) = βT Zj + ϵj

under the assumption that the error terms ϵjs are normally distributed. Then, the regression
coefficient vector β is estimated through a maximum likelihood estimation approach using
the probability density function and the cumulative distribution function of a standard
normal distribution. We have used the censReg package33 in the R software (version 3.6.3)
for estimating the MLE of β from Tobit models in our analyses.

Author Manuscript

Based on 1,000 Monte-Carlo simulations runs, we compare the two different methods by
their average bias, average estimated model-based (theoretical) standard deviation (SD),
average mean squared error (MSE), and average estimated 95% coverage probabilities.
Moreover, we also compute the empirical SD of the estimators for both the methods based
on the Monte-Carlo runs and compare them with the respective theoretical SD of the
estimators for investigating the accuracy of the theoretical variance estimators.

Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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Simulation setting 2: Multiple limits of detection—This simulation setting is similar
to simulation setting 1, except that the total set of observations (n) is divided into three
subsets (subsamples of equal size) and are treated as three independent sets of samples
with different limits of detection. In each of the three subsamples, the lowest quartile of
observed outcomes is set as the lower limit of detection for that subsample. This simulation
setting mimics the scenario where the same biomarker is being evaluated using different
measuring instruments (or assays) leading to different limits of detections. Under this
simulation setting, we consider three different LOD with an overall percentage of below
LOD observations as either of 10% or 25% in the full sample of size n.

Author Manuscript

We apply the semiparametric PV model for estimating the regression parameters. The
application of the Tobit model, however, is limited in this setting since the standard Tobit
model has been developed to model data having only one lower LOD. Since this setting
has multiple LODs to be handled in the same analysis, we fit separate likelihood based
Tobit models for each of the three sets of data which have different lower LODs and
pool the estimates from these three models to obtain a final weighted estimate where the
weights are based on the sample sizes of the three datasets. The average bias, theoretical
SD, empirical SD, MSE and 95% coverage probabilities are calculated based on 1000
Monte-Carlo simulation runs.
3.2

Results of the Simulations

Author Manuscript

Table 1 presents the results for the extreme-value distributed outcomes having single
detection limit. We observe that between the two methods, the PV model has the lowest
MSE in estimating β1 and β2. Although the bias of estimation for the Tobit model is
lower between the two methods, it produces highly unstable estimates with large standard
deviations resulting in very high MSE. We also note that the bias of both the methods
increase with larger proportion of observations below the LOD. On the other hand, the MSE
decrease with the increased sample size. The estimated coverage probabilities for the Tobit
model are close to the target coverage probability of 0.95 in almost all cases. Despite the fact
the PV method has relatively larger bias, the estimated coverage of the PV model is close to
that of the Tobit model as well as the target coverage probability of 0.95 in the majority of
scenarios with extreme-value distributed outcomes.

Author Manuscript

Table 2 displays the results for the normally distributed outcomes having a single lower
LOD. The Tobit model, has lower bias than the PV method but high SD leading to the higher
MSE. Overall, the PV method has lower MSE than the Tobit model despite being a bit more
biased. With the exception in few scenarios, the estimated coverage probabilities of both the
PV and the Tobit models are close to the target coverage of 0.95. In few scenarios, the Tobit
model slightly overshoots the target coverage, and the PV method has a coverage lower than
the target.
We also provide figures in the supplement that describes the results of some extreme
scenarios of very high proportion of outcomes below the LOD or a very large sample size.
We observe for very large sample size of 1200, the PV model has lower MSE than the
Tobit model for extreme-value distributed responses while the Tobit model’s MSE tends
to be lower in the normally distributed outcomes (Supplementary Figures 1 and 2). The
Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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MSE of both methods, however, tend to decrease with increased sample sizes. In addition,
we observe that the MSE of the PV model is lower than the MSE of the Tobit model
in the majority of the scenarios under a very high rate of 60% outcomes below LOD
(Supplementary Figures 3 and 4). This superiority of the semiparametric PV model as
measured by MSE, holds good for such high proportion of below-LOD outcomes even when
the underlying normality assumption of the parametric Tobit model in satisfied.
To summarize all the results from simulating setting 1, we note that the PV model
outperforms the parametric Tobit model in terms of the MSE, especially for small sample
sizes when the distributional assumptions of the parametric models are not met. Even in
settings where the distributional assumptions of parametric models are met, the performance
of the PV method is at least as good as the parametric model.

Author Manuscript

Tables 3 and 4 present the results for the bias, SD, MSE and coverage of the methods
discussed in simulation setting 2 (multiple detection limits) for extreme-value and normally
distributed outcomes, respectively. We note that the bias of the estimators from both the
semiparametric PV model and the modified Tobit model, explained in Section 3.1, increase
with a larger proportion of observations below LOD, while the MSE values decrease as
sample size increases. The PV method has consistently lower MSE than the Tobit model for
all the simulation scenarios considered in the setting 2. Moreover, for non-normal responses,
the Tobit model can lead to unstable estimation results which is evident from the highly
inflated MSE in estimating β2 (Table 3). This is mainly due to the inaccurate variance
estimation of the Tobit model as reflected by the large difference between the theoretical
and the empirical SD of the Tobit model estimates for β2 (Table 3). The estimated coverage
probabilities of both models are close to the target coverage probability. While the Tobit
model, due to its large variance estimate, has a wider coverage than the PV model in
the majority of the cases, there exists some small sample size scenarios where the PV
model’s estimated coverage exceeds that of the Tobit model (Table 3 and 4). Overall, the
semiparametric PV model is much more robust compared to the parametric Tobit model in
modeling biomarkers restricted by multiple LODs.

Author Manuscript

4.

Data Analysis

4.1

Serum Androgens Analysis from Prostate Cancer Clinical Trial

Author Manuscript

We analyze a prostate cancer trial from CALGB 90401 (Alliance) study34 to demonstrate
the usefulness of our proposed semiparametric method in modeling clinical biomarkers
subjected to LOD. This study is a randomized phase III clinical trial involving 1050 patients
with metastatic castration-resistant prostate cancer where the patients were distributed
between two treatment arms (presence or absence of Bevacizumab). Among the laboratory
variables, measurements on three types of serum androgens were recorded: testosterone (T),
androstenedione (A), and dehydroepiandrosterone (D). Serum androgens are known to play
important roles in prostate cancer progression35. An important goal here is to study the
impact of age on baseline serum biomarker levels in prostate cancer patients. In addition, we
also investigate association between race and the biomarker levels. Similarly, association of
serum levels post-treatment with age, race, and treatment arm can also be investigated.

Pharm Stat. Author manuscript; available in PMC 2021 November 21.
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We apply the semiparametric PV model for each of the serum androgens. Age and race
are considered as covariates for modeling each of the serum androgens separately. Age is
modeled as a continuous variable while race (modeled as white or non-white) is a binary
variable. In post-treatment analysis treatment group is also included as a binary covariate.
The lower limits of detection vary between the three serum androgens depending on their
units of measurement, and the resulting proportion of observations below the lower detection
limits also differ between the three.

Author Manuscript

The LOD for T was 1 unit, while that for A and D were 5 units and 20 units respectively.
At baseline, the percentage of patients with T, A, and D values that are below the LOD are
39%, 18% and 57%, respectively. The median T at baseline using all the samples was 1
unit, while the median T ignoring the observations below the LOD was 3 units. The baseline
median of A using all the samples was 13.5 units while the median ignoring the below LOD
samples was 17 units. For T, the baseline median using all the samples was less than 20 units
and the median ignoring the below LOD values was 51 units. At 6-weeks post treatment,
the percentage of patients with T, A, and D values below the LOD are 78%, 35% and 80%,
respectively.
We use the logarithmic values of each serum measurement for modeling. We fit separate
models at baseline and 6-weeks. We estimate the regression coefficients, and their sandwich
variance estimates in each of the serum androgen PV models, and obtain the z-statistic and
the corresponding p-value from each of the estimated coefficients. We also apply the Tobit
model for each serum androgen and obtain the estimated coefficients and the corresponding
p-values.

Author Manuscript

Table 5 shows the results from modeling of the three serum androgens at baseline using
both the semiparametric PV approach and the Tobit model. We observe that age is negatively
associated with the three serums androgens implying that serum levels tend to decrease
as age increases. For T and D, the negative association with age was highly significant
regardless of the method used. For A regression, the PV model infers marginal significance
for association of A with age (p-value=0.08), while the Tobit model does not show evidence
of association between A and age (p-value= 0.147). This is an interesting result since the
PV model finds an important association between serum androgens and age which the Tobit
model could not due a much larger variance estimate.

Author Manuscript

In Table 6, we present the results for the regression analyses at 6-weeks post-treatment.
The proportions of patients with serum observations below the LOD (non-detects) have
drastically increased at 6-week time compared to the baseline and this could be explained
due to the treatment. Despite the high proportions of observations below the LOD, the
PV model is still able to identify significant negative association between age and T
(p-value=0.030), while the Tobit model fails to identify any association between T and
age (p-value=0.134). These findings of association by the PV model are further supported
by other clinical studies that have reported age to be associated with declines in serum
androgens36,37. This highlights a scenario where the semiparametric PV model can capture a
significant association that is missed by the parametric Tobit model in two separate models
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(baseline and post-treatment). Statistically significant association is observed between A and
treatment arm using both the PV model and the Tobit model.
4.2

Serum Cotinine Analysis from NHANES study

Author Manuscript

Serum Cotinine is a metabolite that can be used as a marker for both active smoking and
passive smoking. In this section, we analyze the NHANES 2003-2004 data to investigate
the effect of age and gender on the serum cotinine levels after adjusting for the smoking
habits of the respondents. The data set included 1901 individuals who had information on
their age, sex, smoking habits, and their serum cotinine levels were measured. From the
data, we observed that 16% of the serum cotinine values were below the LOD. In order
to assess the relationship of age and sex with serum cotinine, we fit censored regression
models with serum cotinine levels as responses, and age, sex, and smoking habit (yes/no) as
the covariates. We use our proposed semiparametric model as well as the parametric Tobit
model for this analysis (Table 7). It is clear that age has positive significant association with
the cotinine levels, while females have lower cotinine levels compared to males (Table 7).
These association results are agreed upon by both the PV model and the Tobit model with
different, but significant, p-values.

5.

Discussion

Author Manuscript
Author Manuscript

This article is motivated by the necessity to develop a modeling approach for analyzing
biomarkers with observations below the LOD that remains robust to misspecifications in
model assumptions. To achieve this goal, we implement a semiparametric model based on
pseudo-values which is free from distributional assumptions. To the best of our knowledge,
we are the first to implement the pseudo-value (PV) approach for modeling biomarkers
below the detection limit. Through our motivating prostate cancer clinical trial example,
we emphasize the utility of our proposed semiparametric PV model approach in identifying
important association between a LOD-restricted serum androgen biomarker and prognostic
factor when the standard parametric Tobit model fails. Moreover, through simulation studies
we show that our method produces lower MSE than the standard parametric regression
model when the underlying distributional assumptions are violated. Even in simulated
data where the distributional assumptions of the standard parametric models are met, the
performance of our semiparametric model is competitive to that of the parametric models.
In multi-center trials, often biomarkers are measured at institutional laboratories and LODs
can differ between these resources. Unlike the standard Tobit model which fits separate
likelihoods for different LODs resulting in multiple estimates of the same parameter of
biomarker association, the semiparametric PV method can be easily applied to multiple
lower detection limits to fit a single model on the same biomarker due to the different
sources. Through the prostate cancer trial data, we show that, even in presence of high
percentages of non-detects in serum androgens, our semiparametric method can identify
signification biomarker associations.
Returning to our motivational example in prostate cancer, it has been reported that serum
androgen levels have strong association with age of the patients36,37. In the 6-week post
treatment analysis, the serum androgen levels decline to great extents from the baseline
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levels, due to the treatment effect, leading to the higher proportions of observations below
the LOD than the baseline. Even in such a scenario, the semiparametric PV model is
still able to identify significant negative association between age and T (p-value=0.030),
while the Tobit model fails to identify any association between T and age (p-value=0.134).
This raises the possibility of substantial loss of power of the parametric model due to the
departure from the underlying assumptions and highlights the robustness of the PV model.

Author Manuscript

In summary, the semiparametric model based on pseudo-values is easy to use and
implement. Our semiparametric PV model does not require distributional assumptions, it
is robust to model misspecification than the standard parametric models. The pseudo-values
are based on the leave-one-out jackknife technique. A typical pseudo-value for a unit
measures the contribution of the unit on the overall mean of the response variable even
if that unit has a censored response, i.e., a value below LOD. Hence, in the presence
of multiple LODs in the same data, the PV model incorporates more information on
the impact of the below LOD samples on the overall summary statistic, compared to an
ad-hoc substitution approach that merely replaces all the observations below LOD by an
artificial value, e.g., LOD/2. Investigators are encouraged to use this approach whenever
they encounter single or multiple observations below the LOD. The use of biomarkers will
continue to be an important area of research not only in diagnosing patients but will be also
used in treating patients with disease.

Author Manuscript

We have focused in this article on the modeling of biomarkers as responses. For the serum
androgen data, including baseline serum androgen as a covariate in modeling post-treatment
serum level will lead to a more complicated modeling scenario where both response and
one of the covariates are restricted to an LOD. As a future research, we plan to examine
this complex modeling scenario and aim to develop methods for addressing it. We will also
consider modelling the changes of serum levels from baseline to 6-weeks as many patients
have serum levels recorded as below LOD at both time points.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1.

Author Manuscript

Simulation results based on 1000 Monte-Carlo runs with Weibull error distribution and single lower limit of
detection (LOD)
n = 60

β1

β2

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

PV
model

−0.139

0.872
(0.915)

1.643
(0.926)

−0.271

Tobit
model

−0.064

0.989
(1.006)

2.018
(0.936)

−0.108

Theoretial
(Empirical)
SD

10% below LOD

25% below LOD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

0.698
(0.746)

1.135
(0.922)

−0.135

0.901
(0.959)

1.763
(0.936)

−0.262

0.727
(0.778)

1.213
(0.912)

0.923
(0.954)

1.793
(0.948)

−0.079

0.995
(1.059)

2.135
(0.942)

−0.098

0.926
(0.986)

1.852
(0.936)

n = 300

Author Manuscript

β1

β2

10% below LOD

25% below LOD

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretial
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

PV
model

−0.099

0.398
(0.409)

0.336
(0.944)

−0.241

0.312
(0.324)

0.261
(0.856)

−0.097

0.411
(0.432)

0.366
(0.926)

−0.245

0.325
(0.330)

0.275
(0.890)

Tobit
model

−0.031

0.445
(0.450)

0.402
(0.952)

−0.050

0.410
(0.420)

0.348
(0.944)

−0.034

0.452
(0.473)

0.430
(0.940)

−0.068

0.416
(0.419)

0.353
(0.940)

Author Manuscript
Author Manuscript
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Table 2.

Author Manuscript

Simulation results based on 1000 Monte-Carlo runs with Normal Error distribution and single (LOD)
n = 60

β1

β2

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

PV
model

−0.165

0.921
(0.996)

1.894
(0.934)

−0.222

Tobit
model

−0.060

1.044
(1.000)

2.312
(0.940)

0.050

Theoretial
(Empirical)
SD

10% below LOD

25% below LOD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

0.797
(0.905)

1.528
(0.904)

−0.092

0.947
(1.095)

1.916
(0.928)

−0.249

0.842
(0.884)

1.564
(0.926)

1.067
(1.197)

2.600
(0.922)

0.008

1.051
(1.104)

2.334
(0.936)

−0.012

1.069
(1.121)

2.414
(0.934)

n=300

β1

β2

Author Manuscript

10% below LOD

25% below LOD

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretial
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(coverage)

PV
model

−0.218

0.383
(0.364)

0.330
(0.892)

−0.293

0.353
(0.336)

0.325
(0.852)

−0.180

0.396
(0.389)

0.342
(0.920)

−0.262

0.367
(0.356)

0.331
(0.896)

Tobit
model

−0.017

0.466
(0.425)

0.400
(0.960)

−0.017

0.478
(0.444)

0.426
(0.960)

0.015

0.474
(0.450)

0.427
(0.958)

0.013

0.484
(0.463)

0.449
(0.954)

Author Manuscript
Author Manuscript
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Table 3.

Author Manuscript

Simulation results based on 1000 Monte-Carlo runs with Weibull Error distribution with multiple LOD
n = 60

β1
10% below LOD

β2

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

PV
model

−0.157

0.871
(0.937)

1.688
(0.942)

−0.213

Tobit
model

−0.048

1.012
(1.108)

2.283
(0.926)

−0.086

Theoretical
(Empirical)
SD

10% below LOD

25% below LOD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

0.788
(0.856)

1.419
(0.916)

−0.174

0.901
(0.960)

1.776
(0.922)

−0.216

0.818
(0.868)

1.480
(0.916)

0.949
(1.034)

2.003
(0.924)

−0.118

1.947
(1.168)

455.2
(0.928)

−0.162

3.647
(1.115)

1257.2
(0.928)

n = 300

β1

β2

Author Manuscript

10% below LOD

25% below LOD

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

PV
model

−0.093

0.414
(0.425)

0.363
(0.938)

−0.193

0.354
(0.360)

0.293
(0.910)

−0.091

0.428
(0.454)

0.398
(0.930)

−0.189

0.368
(0.391)

0.325
(0.898)

Tobit
model

−0.028

0.447
(0.456)

0.409
(0.950)

−0.061

0.415
(0.427)

0.359
(0.942)

−0.033

0.451
(0.480)

0.435
(0.944)

−0.070

0.417
(0.447)

0.380
(0.928)

Author Manuscript
Author Manuscript
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Table 4.

Author Manuscript

Simulation results based on 1000 Monte-Carlo runs with Normal Error distribution with multiple LOD
n = 60

β1

β2

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

PV
model

−0.140

0.942
(1.015)

1.964
(0.934)

−0.226

Tobit
model

−0.045

1.064
(1.161)

2.507
(0.924)

−0.045

Theoretical
(Empirical)
SD

10% below LOD

25% below LOD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

0.875
(0.948)

1.745
(0.934)

−0.069

0.967
(1.018)

1.985
(0.936)

−0.159

0.904
(0.969)

1.796
(0.918)

1.093
(1.197)

2.662
(0.928)

0.002

1.042
(1.153)

2.429
(0.926)

−0.030

1.065
(1.178)

2.543
(0.922)

n = 300

β1

β2

Author Manuscript

10% below LOD

25% below LOD

10% below LOD

25% below LOD

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

Bias

Theoretical
(Empirical)
SD

MSE
(Coverage)

PV
model

−0.207

0.388
(0.372)

0.334
(0.894)

−0.266

0.365
(0.350)

0.328
(0.872)

−0.168

0.401
(0.393)

0.345
(0.922)

−0.232

0.379
(0.366)

0.333
(0.912)

Tobit
model

−0.014

0.468
(0.437)

0.411
(0.958)

−0.016

0.480
(0.454)

0.438
(0.956)

0.020

0.472
(0.454)

0.430
(0.956)

0.011

0.483
(0.465)

0.450
(0.948)

Author Manuscript
Author Manuscript
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Table 5.

Author Manuscript

Results from the semiparametric PV model and Tobit model analysis of serum androgens at baseline from the
CALGB 90401 prostate cancer data
Estimated regression coefficients
Testosterone model

Androstenedione model

Dehydroepiandrosterone model

Covariates
PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

Age

−0.011 (0.004)

−0.026 (0.004)

−0.006 (0.080)

−0.006 (0.147)

−0.020 (<0.001)

−0.044 (<0.001)

Race (White
vs. others)

0.107 (0.280)

0.110 (0.636)

−0.062 (0.488)

−0.080 (0.476)

0.033 (0.636)

0.046 (0.777)

Author Manuscript
Author Manuscript
Author Manuscript
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Table 6.

Author Manuscript

Results from the semiparametric PV model and Tobit model analysis of serum androgens at 6-weeks post
treatment from the CALGB 90401 prostate cancer data
Estimated regression coefficients
Testosterone model

Androstenedione model

Dehydroepiandrosterone model

Covariates
PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

PV model
coefficient (pvalue)

Tobit model
coefficient (pvalue)

Age

−0.009 (0.030)

−0.026 (0.134)

−0.002 (0.568)

0.000 (0.999)

−0.008 (0.001)

−0.029 (0.001)

Race (White
vs. others)

−0.124 (0.329)

−0.324 (0.469)

−0.058 (0.446)

−0.087 (0.458)

−0.122 (0.065)

−0.635 (0.003)

Treatment Arm

0.080 (0.263)

0.438 (0.139)

0.101 (0.046)

0.177 (0.019)

0.055 (0.116)

0.434 (0.006)

Author Manuscript
Author Manuscript
Author Manuscript
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Table 7.

Author Manuscript

Results from the modeling of serum cotinine from NHANES 2003-04 study to determine the effects of age
and gender on cotinine levels obtained after adjusting for smoking habits
Covariates

Regression Coefficient (p-value)
PV model

Tobit model

Age

0.134 (<0.0001)

0.147 (<0.0001)

Gender (Female against male)

−0.418 (0.0003)

−0.517 (0.0001)

Smoking status (Smoker against non-smoker)

2.104 (<0.0001)

2.348 (<0.0001)

Author Manuscript
Author Manuscript
Author Manuscript
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